Literature DB >> 21800131

Up-regulation of metallothionein gene expression in parkinsonian astrocytes.

Gregory J Michael1, Sharmin Esmailzadeh, Linda B Moran, Lynne Christian, Ronald K B Pearce, Manuel B Graeber.   

Abstract

The role of glial cells in Parkinson's disease (PD) is unclear. We have previously reported a striking up-regulation of DnaJB6 heat shock protein in PD substantia nigra astrocytes. Whole genome transcriptome analysis also indicated increased expression of metallothionein genes in substantia nigra and cortex of sporadic PD cases. Metallothioneins are metal-binding proteins in the CNS that are released by astrocytes and associated with neuroprotection. Metallothionein expression was investigated in 18 PD cases and 15 non-PD controls using quantitative real-time polymerase chain reaction (qRT-PCR), in situ hybridisation (ISH) and immunocytochemistry (ICC). We observed a strong increase in the expression of metallothioneins MT1E, MT1F, MT1G, MT1H, MT1M, MT1X and MT2A in both PD nigra and frontal cortex. Expression of LRP2 (megalin), the neuronal metallothionein receptor was also significantly increased. qRT-PCR confirmed metallothionein up-regulation. Astrocytes were found to be the main source of metallothioneins 1 and 2 based on ISH results, and this finding was confirmed by ICC. Our findings demonstrate metallothionein expression by reactive astrocytes in PD nigra and support a neuroprotective role for these cells. The traditional view that nigral astrocytes are non-reactive in PD is clearly incorrect. However, it is possible that astrocytes are themselves affected by the disease process which may explain their comparatively modest and previously overlooked response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800131     DOI: 10.1007/s10048-011-0294-5

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  68 in total

1.  The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.

Authors:  B Mirza; H Hadberg; P Thomsen; T Moos
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins.

Authors:  Manuchair Ebadi; Sushil K Sharma; Pedram Ghafourifar; Holly Brown-Borg; H El Refaey
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

3.  Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury.

Authors:  Roger S Chung; Milena Penkowa; Justin Dittmann; Carolyn E King; Carole Bartlett; Johanne W Asmussen; Juan Hidalgo; Javier Carrasco; Yee Kee J Leung; Adam K Walker; Samantha J Fung; Sarah A Dunlop; Melinda Fitzgerald; Lyn D Beazley; Meng I Chuah; James C Vickers; Adrian K West
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

4.  Altered expression of metallothionein-I and -II and their receptor megalin in inherited photoreceptor degeneration.

Authors:  Kirsten A Wunderlich; Thierry Leveillard; Milena Penkowa; Eberhart Zrenner; Maria-Thereza Perez
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-31       Impact factor: 4.799

5.  Quantitative immunogold study of increased expression of metallothionein-I/II in the brain perivascular areas of diabetic scrapie-infected mice.

Authors:  Andrzej W Vorbrodt; Danuta H Dobrogowska; Harry C Meeker; Richard I Carp
Journal:  J Mol Histol       Date:  2006-09-21       Impact factor: 2.611

6.  Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases.

Authors:  Jacqueline Mikol; Claude Vital; Michel Wassef; Philippe Chappuis; Joël Poupon; Monique Lecharpentier; France Woimant
Journal:  Acta Neuropathol       Date:  2005-09-30       Impact factor: 17.088

7.  Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity.

Authors:  Muralikrishnan Dhanasekaran; Christian B Albano; Lori Pellet; Senthilkumar S Karuppagounder; Subramaniam Uthayathas; Vishnu Suppiramaniam; Holly Brown-Borg; Manuchair Ebadi
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

Review 8.  Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes.

Authors:  Sook-Jeong Lee; Jae-Young Koh
Journal:  Mol Brain       Date:  2010-10-26       Impact factor: 4.041

9.  Zn and Cu alteration in connection with astrocyte metallothionein I/II overexpression in the mouse brain upon physical stress.

Authors:  Mariano Beltramini; Cristina Di Pisa; Pamela Zambenedetti; Werner Wittkowski; Eugenio Mocchegiani; Massimo Musicco; Paolo Zatta
Journal:  Glia       Date:  2004-07       Impact factor: 7.452

10.  Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+.

Authors:  B R Ransom; D M Kunis; I Irwin; J W Langston
Journal:  Neurosci Lett       Date:  1987-04-10       Impact factor: 3.046

View more
  20 in total

Review 1.  Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress.

Authors:  Carla Garza-Lombó; Yanahi Posadas; Liliana Quintanar; María E Gonsebatt; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2018-03-28       Impact factor: 8.401

Review 2.  Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease.

Authors:  Aracely Garcia-Garcia; Laura Zavala-Flores; Humberto Rodriguez-Rocha; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2012-05-03       Impact factor: 8.401

3.  Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice.

Authors:  Shinki Murakami; Ikuko Miyazaki; Norio Sogawa; Ko Miyoshi; Masato Asanuma
Journal:  Neurotox Res       Date:  2014-06-13       Impact factor: 3.911

Review 4.  The role of astrocyte mitochondria in differential regional susceptibility to environmental neurotoxicants: tools for understanding neurodegeneration.

Authors:  Laura L Kubik; Martin A Philbert
Journal:  Toxicol Sci       Date:  2015-03       Impact factor: 4.849

5.  An investigation of modifying effects of metallothionein single-nucleotide polymorphisms on the association between mercury exposure and biomarker levels.

Authors:  Yi Wang; Jaclyn M Goodrich; Brenda Gillespie; Robert Werner; Niladri Basu; Alfred Franzblau
Journal:  Environ Health Perspect       Date:  2012-01-09       Impact factor: 9.031

6.  A network view on Parkinson's disease.

Authors:  Sreedevi Chandrasekaran; Danail Bonchev
Journal:  Comput Struct Biotechnol J       Date:  2013-07-14       Impact factor: 7.271

Review 7.  Copper and copper proteins in Parkinson's disease.

Authors:  Sergio Montes; Susana Rivera-Mancia; Araceli Diaz-Ruiz; Luis Tristan-Lopez; Camilo Rios
Journal:  Oxid Med Cell Longev       Date:  2014-01-08       Impact factor: 6.543

8.  Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease.

Authors:  Alexandra Dumitriu; Javad Golji; Adam T Labadorf; Benbo Gao; Thomas G Beach; Richard H Myers; Kenneth A Longo; Jeanne C Latourelle
Journal:  BMC Med Genomics       Date:  2016-01-21       Impact factor: 3.063

9.  Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice.

Authors:  Kim M Gerecke; Yun Jiao; Viswajeeth Pagala; Richard J Smeyne
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

Review 10.  Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease.

Authors:  Ikuko Miyazaki; Masato Asanuma
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.